Neogen (NEOG) Q4 2025 Earnings Call Transcript

Q4 revenue was $225M (core revenue down ~2.9%) with adjusted EBITDA of $41M (18% margin) and adjusted EPS of $0.05, roughly half year-ago levels. Management recorded a $598M non-cash goodwill impairment tied to the 3M Food Safety acquisition, ended the quarter with $900M gross debt and $129M cash, and reported roughly breakeven free cash flow. Guidance for FY26 is revenue $820M–$840M and adjusted EBITDA $165M–$175M, incorporating a $10M tariff headwind; Petrifilm insourcing (17 SKUs over 4–5 quarters), genomics divestiture progress, and operational fixes in sample collection are key catalysts to monitor amid an imminent CEO transition.

Analysis

The large non‑cash writedown fundamentally resets expectations: investors should treat near‑term earnings as reflecting integration and restructuring noise rather than a permanent demand collapse. That matters because it forces management into a two‑front battle—operational turnarounds and balance sheet repair—which typically compresses discretionary R&D and M&A optionality for 12–24 months and elevates the probability of additional portfolio pruning if liquidity becomes more constrained.

Operationally, the phased insourcing of a high-volume consumable creates a backloaded margin opportunity but also a multi‑quarter execution cliff: any slip in SKU certification or capacity ramp will propagate as elevated scrap, temporary labor, and mix drag that can outsize modest topline swings. Coupled with tariff volatility, this amplifies negative operating leverage — small declines in volumes or uptime translate into outsized margin moves until automation and BOM stabilization are proven.

The regulatory adoption of the firm’s detection platform is the strategic asymmetry here: when public agencies standardize on an assay ecosystem, recurring consumables and software lock‑ins create durable annuity‑like revenues, but timing and procurement cycles remain lumpy. Management turnover and recent governance fixes lower headline governance risk, which should make eventual commercial wins more credible to buyers — a potential multi‑quarter re‑rating catalyst if execution normalizes and divestiture proceeds are redeployed to debt reduction or targeted reinvestment.

Key Decisions for Investors

• Buy a conservative bullish option structure on NEOG to capture backloaded margin upside: initiate a 9–12 month call spread (buy near‑ATM call / sell ~30% OTM call) sized ~1–2% of NAV. Rationale: asymmetric payoff if in‑house SKU certification and assay adoption validate margin improvement; risk limited to premium, target 2–4x payoff if execution normalizes.
• Establish a tactical hedge against lingering operational misses by buying short‑dated (3–6 month) NEOG puts equal to ~0.5–1% of NAV on any >10% intraday bounce. Rationale: protects against downside if sample collection or tariff costs re‑accelerate; premium is a reasonable insurance cost versus outright short exposure.
• Pair trade for relative safety: long MMM (8–12 month horizon) vs. short NEOG (equal dollar) sized to target a 10–15% relative move. Rationale: rotate into a diversified industrial with cleaner cash flow and lower operational execution risk while shorting the single‑name execution/cyclicality headline; set stop‑loss 12% and target relative outperformance of 20%.
• Watchlist triggers (not trades): take profit on bullish structures or add to longs only after two confirmations: (1) sustained in‑house SKU production at commercial rates for two consecutive quarters, and (2) sequential gross margin improvement ex‑inventory charges. These events materially compress execution risk and should be used to re‑rate position sizing.